de Teresa E
Servicio de Cardiología, Hospital Universitario, Málaga.
Rev Esp Cardiol. 1997 May;50(5):300-3.
Congestive heart failure is an increasing cause of mortality among the aging population. The current management approaches have increased the survival of patients with congestive heart failure, although the mortality rate remains high. Thus, any effort to reduce mortality in this condition seems justified. Beta-adrenergic blocking agents have shown to improve functional class and the ventricular function of heart failure patients; the use of these agents should be considered in congestive heart failure patients unless an increase in mortality with betablockers can be demonstrated. In fact, beta-blockers reduce mortality, as the recent study of carvedilol has demonstrated. Therefore, beta adrenergic blocking agents should be incorporated into the strategies of management of patients with congestive heart failure.
充血性心力衰竭在老年人群中的致死率日益上升。尽管目前的治疗方法提高了充血性心力衰竭患者的生存率，但死亡率仍然很高。因此，任何降低这种疾病死亡率的努力似乎都是合理的。β-肾上腺素能阻滞剂已被证明可改善心力衰竭患者的功能分级和心室功能；除非能证明β受体阻滞剂会增加死亡率，否则应考虑在充血性心力衰竭患者中使用这些药物。事实上，正如最近对卡维地洛的研究所表明的，β受体阻滞剂可降低死亡率。因此，β肾上腺素能阻滞剂应纳入充血性心力衰竭患者的治疗策略中。
